Organon & Co. (OGN): Revenue
$6.22B
Year ended 2025-12-31
$6.13B
Trailing 12 months to 2026-06-30
+0.2%
3-year compound annual growth
-1.0%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.22B | -2.9% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $6.40B | +2.2% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $6.26B | +1.4% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $6.17B | -2.1% | 2025-11-10, From 2022-01-01 |
| 2021-12-31 | $6.30B | -3.5% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $6.53B | -16.0% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $7.78B | n/a | 2022-03-21, From 2019-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Organon & Co. (OGN) | 2025-12-31 | $6.22B | -2.9% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $5.34B | +40.2% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $4.71B | +6.2% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $4.27B | +4.9% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $4.25B | -2.8% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $9.47B | +2.3% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $10.27B | +6.7% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $3.71B | +65.2% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $3.22B | +12.9% |
Compare OGN, ONC, ELAN, JAZZ side by side · Screen every company in Pharmaceutical Preparations ↗